Metagenomi, Inc. Common Stock
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Metagenomi, Inc. (Nasdaq: MGX) is a genetic medicines company that develops in vivo therapeutics using a proprietary metagenomics-derived genome editing toolbox to enable curative treatments for patients with genetic diseases. The company's toolbox comprises nuclease-based genome editors for precise cuts; base editors for single-base changes; RNA-mediated integration systems including prime editing and small RNA integration (RIGS); and DNA-mediated large payload integration systems such as CRISPR-associated transposases (CASTs); with a focus on applications for secreted protein deficiencies like hemophilia A via its lead wholly-owned candidate MGX-001, refractory hypertension, cardiovascular diseases, and Wilson's disease. Metagenomi operates primarily in the United States, targeting high-value indications with well-defined regulatory pathways, and maintains a wholly-owned pipeline alongside partnered programs. Founded in 2016 and headquartered at 5959 Horton Street, 7th Floor, Emeryville, California, the company went public in February 2024. Recent developments include positive preclinical data for MGX-001 demonstrating durable Factor VIII (FVIII) activity up to 19 months in non-human primates with curative potential, supporting a planned pre-IND meeting in 4Q 2025 and IND/CTA submissions in 4Q 2026; strategic pipeline prioritization on MGX-001, other secreted protein programs, and cardiometabolic collaborations while deprioritizing early discovery efforts and reducing workforce by 25% to extend cash runway into 4Q 2027; advancement of the Ionis Pharmaceuticals collaboration toward development candidate nominations in 2025 across two cardiometabolic targets; and achievement of a milestone with Affini-T Therapeutics establishing cGMP gene editing reagents to support an IND filing for T-cell receptor-based cancer therapies.
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference
Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
Metagenomi, Inc. (NASDAQ:MGX) Receives $10.00 Consensus PT from Analysts
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Metagenomi (MGX) to Release Earnings on Wednesday
Metagenomi, Inc. (NASDAQ:MGX) Receives $10.00 Consensus Target Price from Analysts
Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
Metagenomi Therapeutics, Inc. (MGX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
MGX Resources Limited (MTGRY) Q2 2026 Earnings Call Prepared Remarks Transcript
Hiab expands US footprint with appointment of MGX Equipment Services as new dealer in 13 states
Metagenomi (NASDAQ:MGX) Shares Down 1.2% – Here’s Why
MGX Resources Limited (MTGRY) Shareholder/Analyst Call Prepared Remarks Transcript
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook